Separate names with a comma.
Of course every scientist that fails should just quit.
According to his Linkedin, Will McLean (on whose research FX-322 was founded on) left Frequency Therapeutics in April 2022 and is now Chief...
Great news.
There is absolutely no reason to assume that the reason FX-322 failed is because the supposed regenerated hair cells had no nerve endings. Hair...
And if I might add: the hearing improvement must last long term. Some FX-322 patients lost their ‘gains’ after 1/2 years. Either the hair cell is...
Yes but lab findings don’t always translate into real life findings. It would be interesting to study temporal bones of patients who participated...
We actually don’t, not in humans. We only know the drug gets in the cochlea (they did two studies on this with patients who were about to be...
Fully agreed. I thought something was weird when they kept changing the goal posts after every trial. They already did that in 2019 when almost...
Yes, sudden hearing loss/deafness happens all the time, but I do agree that judging from what we know of the efficacy of FX-322, he seems to be...
Interesting. I wonder when the gentleman participated in the trial. If it was one of the earlier ones, his recovery could be attributed to the...
Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss...
Otoprotective drugs are interesting to me as a hearing loss patient, because they can provide insights with regards to getting drugs into the...
Looks to me as if PIPE-505 did not achieve the results they had hoped for.
Just watched this Fireside chat by Frequency Therapeutics:...
It was a missed opportunity. The presenter asks the question at 25:45. Franck says ‘there’s a story there that kind of makes sense’ but he doesn’t...
